The Pharmacy Compounding Advisory Committee narrowly voted to recommend adding six peptides to the official drug compounding list.

The Pharmacy Compounding Advisory Committee narrowly voted to recommend adding six peptides—BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax—to an approved list of ingredients for specialty pharmacies. This non-binding recommendation allows licensed pharmacies to create custom medications for patients with a doctor's prescription. The decision reflects a push to move popular compounds from the unregulated "gray market" into a regulated framework. While the committee members, many of whom run peptide clinics, argued that the move reduces harm by ensuring better quality control, FDA staff scientists remained skeptical. The agency's own reviewers unanimously opposed the additions, citing a lack of robust clinical trial data and potential risks of immune reactions. Robert F. Kennedy Jr., who oversees the FDA as the Health and Human Services Secretary, expressed support for the move, viewing current restrictions as unnecessary barriers. However, drug manufacturers warned that the list does not grant full FDA approval, noting that the peptides still bypass the rigorous clinical trials required for standard medications. The FDA must now review the records before publishing proposed rules.

Sources